Dr. Ramon Valdez walked into his Manila hospital's January 7th cardiology meeting carrying the three-year BIOADAPTOR-RCT results. The numbers were stark: 2.7% target lesion failure with DynamX versus 7.2% with standard drug-eluting stents.
His procurement director cut him off within minutes. "We already have three stent contracts."
Two senior partners piled on. Why justify premium pricing for 4.5% absolute risk reduction? Their patient population couldn't afford experimental technology.
Valdez pulled out the INFINITY-SWEDEHEART small vessel subset. Zero target lesion failures with DynamX. Zero. The room went quiet.
By Thursday, three colleagues had requested supervised cases. The department chair scheduled a February protocol review.